Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clozapine-related Immunodeficiency in Parkinson's Disease
NCT06634641Phase 4Recruiting
- Sponsor
- CHU Amiens-Picardie
- Start
- Oct 2024
- Primary completion
- Sep 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clozapine in psychosis, sponsored by CHU Amiens-Picardie. Primary endpoint: Change in serum IgG levels at 6 months. Started Oct 2024; status: recruiting.
02
Drugs
clozapine
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT06634641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634641.